2. Signaling Pathways
  3. Others
  4. Others

Others

 
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-14905
    Uridine triacetate
    		99.95%
    Uridine triacetate (Tri-O-acetyl uridine) is an orally active proagent of Uridine (HY-B1449). Uridine triacetate is quickly absorbed in the gut, and is rapidly deacetylated in the circulation to yield free uridine. Uridine triacetate is used for the research of 5-fluorouracil (5-FU) and capecitabine toxicity, or early-onset cardiac or central nervous system (CNS).
    Uridine triacetate
  • HY-150014
    AMT-NHS
    		98.55%
    AMT-NHS is an RNA-protein crosslinker. AMT-NHS is composed of a psoralen derivative and an N-hydroxysuccinimide ester group which react with RNA bases and primary amines of protein, respectively. AMT-NHS can penetrate into living yeast cells and crosslink Cbf5 to H/ACA snoRNAs with high specificity. AMT-NHS induces different crosslinking patterns and targets both single- and double-stranded regions of RNA. AMT-NHS can be used for capturing diverse RNA-protein interactions in cells.
    AMT-NHS
  • HY-147056
    PKRA83
    		98.04%
    PKRA83 (PKRA7) is a potent prokineticin (PK2) antagonist, which can compete for the binding of PK2 to its receptors PKR1 and PKR2. PKRA83 potently inhibits PK2 receptors, with IC50 values of 5.0 nM and 8.2 nM for PKR1 and PKR2, respectively. PKRA83 has anticancer, anti-arthritis and anti-angiogenic activities. PKRA83 can penetrate the blood-brain barrier.
    PKRA83
  • HY-109520
    Glatiramer acetate
    		≥98.0%
    Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, inhibits Experimental autoimmune encephalomyelitis (EAE), and can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression.
    Glatiramer acetate
  • HY-107794
    Clodronate disodium tetrahydrate
    		99.86%
    Clodronate disodium tetrahydrate (Disodium clodronate tetrahydrate) is first-generation bisphosphonate, with anti-osteoporotic, anti-inflammatory and analgesic effects. Clodronate disodium tetrahydrate is a selective, potent, reversible and Cl- competitive vesicular nucleotide transporter (VNUT) inhibitor, with an IC50 of 15.6 nM. Clodronate disodium tetrahydrate inhibits vesicular ATP release from neurons and reduces chronic neuropathic and inflammatory pain.
    Clodronate disodium tetrahydrate
  • HY-137978A
    Ezurpimtrostat hydrochloride
    		Inhibitor 99.29%
    Ezurpimtrostat hydrochloride (compound 2-3) is a potent and orally active anti-fibrotic agent. Ezurpimtrostat hydrochloride reduces significantly the liver fibrosis in DEN (diethyl nitrosamine) cirrhotic rat model. Ezurpimtrostat hydrochloride can be used for the research of fibrosis, cancer, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases .
    Ezurpimtrostat hydrochloride
  • HY-15642
    TD-198946
    		99.93%
    TD-198946, a thienoindazole derivative, is a potent chondrogenic agent.
    TD-198946
  • HY-111365
    TES-1025
    		Inhibitor 98.12%
    TES-1025 is a potent and selective human α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) inhibitor with an IC50 of 13 nM.
    TES-1025
  • HY-125145
    AA92593
    		98.60%
    AA92593 is a selective and competitive melanopsin OPN4 antagonist.
    AA92593
  • HY-102081
    2OH-BNPP1
    		99.65%
    2OH-BNPP1 is an inhibitor of BUB1 kinase, a Ser/Thr kinase, used for the treatment of cancer.
    2OH-BNPP1
  • HY-148788
    Osivelotor
    		99.83%
    Osivelotor is an orally effective small molecule. Osivelotor is an allosteric regulator of deoxyhemoglobin S (HbS). Osivelotor increases the affinity of HbS to oxygen, inhibits HbS polymerization, and thus prevents erythrocyte sickling in the blood. Osivelotor can be used for research of sickle cell disease (SCD) .
    Osivelotor
  • HY-156483
    TT-012
    		99.89%
    TT-012 specifically binds to dynamic MITF and destroys the latter's dimer formation and DNA-binding ability. TT-012 inhibits the transcriptional activity of MITF in B16F10 melanoma cells. TT-012 inhibits the growth of high-MITF melanoma cells, and inhibits the tumor growth and metastasis with tolerable toxicity to liver and immune cells in animal models.
    TT-012
  • HY-W176171
    PU.1-IN-1
    		99.72%
    PU.1-IN-1 (compound A11) is a potent PU.1 inhibitor with an IC50 of 2 nM. PU.1-IN-1 has anti-inflammatory properties.
    PU.1-IN-1
  • HY-N7698B
    Hexa-N-acetylchitohexaose
    		99.81%
    Hexa-N-acetylchitohexaose is an inducer of disease resistance in crop plants, which could elicit an increase of lignification-related and antioxidative enzymes in soybean plants. Hexa-N-acetylchitohexaose is a substrate of lysozyme. Hexa-N-acetylchitohexaose shows antitumor effect.
    Hexa-N-acetylchitohexaose
  • HY-148509
    PhosTAC5
    		99.94%
    PhosTAC5 is a phosphorylation targeting chimera (PhosTAC) molecule composed of a linker with fivePEG groups. PhosTAC5 induces dephosphorylation of PDCD4 and FOXO3a.
    PhosTAC5
  • HY-148226
    20-5,14-HEDGE
    		98.74%
    20-5,14-HEDGE is a 20-HETE analog. 20-5,14-HEDGE protects against lung ischemic reperfusion injury in rats.
    20-5,14-HEDGE
  • HY-124830
    SPA70
    		≥99.0%
    SPA70 is a potent and selective antagonist of human pregnane X receptor (hPXR), with an IC50 of 540 nM (Ki=390 nM). SPA70 can enhance the chemosensitivity of cancer cells.
    SPA70
  • HY-10499
    PH-064
    		99.88%
    PH-064 (BIM-46187) is an inhibitor of heterotrimeric G-protein complex.
    PH-064
  • HY-157414
    Azide-A-DSBSO crosslinker
    Azide-A-DSBSO crosslinker is a mass spectrometry (MS)-cleavable, membrane-permeable, homobifunctional, azide-labeled, acid-cleavable cross-linked peptide. Azide-A-DSBSO crosslinker enables the study of protein-protein interactions via cross-linking mass spectrometry (XL-MS).
    Azide-A-DSBSO crosslinker
  • HY-112158
    NSC139021
    		Inhibitor 99.86%
    NSC139021 (ERGi-USU) is a RIOK2 inhibitor with anticancer activity. RIOK2 can highly selectively inhibit the growth of ERG-positive cancer cells with IC50s???of 30-400 nM against cell lines. RIOK2 also causes cell cycle arrest and apoptosis in glioblastoma via induction of Skp2 and Skp2-p27/p21-Cyclin E/CDK2-pRb signaling.
    NSC139021
Cat. No. Product Name / Synonyms Application Reactivity